US Bancorp’s ADC Therapeutics ADCT Stock Holding History

US Bancorp’s Portfolio ADCT Stock Details ADCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-300	Closed	-$269	–	3971
2023 Q3	$269	Hold	300	–	–	﹤0.01%	3901
2023 Q2	$645	Hold	300	–	–	﹤0.01%	3854
2023 Q1	$585	Hold	300	–	–	﹤0.01%	3933
2022 Q4	$1.15K	Hold	300	–	–	﹤0.01%	3895
2022 Q3	$1K	Hold	300	–	–	﹤0.01%	3905
2022 Q2	$2K	Sell	300 -50	-14%	-$473	﹤0.01%	3788
2022 Q1	$5K	Sell	350 -150	-30%	-$2.38K	﹤0.01%	3584
2021 Q4	$10K	Hold	500	–	–	﹤0.01%	3407
2021 Q3	$14K	Sell	500 -600	-55%	-$15.4K	﹤0.01%	3284
2021 Q2	$27K	Sell	1,100 -700	-39%	-$16.2K	﹤0.01%	2968
2021 Q1	$44K	Buy	+1,800	New	+$52.1K	﹤0.01%	2638

Other funds holding ADCT

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

VCG

Vantage Consulting Group Virginia Beach, Virginia $19.7M AUM 280.87% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

US Bancorp's ADCT Position: Q4 2023 in Review

US Bancorp sold out of ADC Therapeutics (ADCT) in Q4 2023, closing a stake of 300 shares — an estimated $269 sold.

US Bancorp first reported a position in ADCT in Q1 2021 and held it in 11 quarters. The position peaked at $44K in Q1 2021. 37 funds tracked by Wall St. Rank hold ADCT as of Q4 2023.

US Bancorp reported no remaining ADC Therapeutics position as of Q4 2023 after selling out during the quarter.
US Bancorp sold 300 ADC Therapeutics shares in Q4 2023, an estimated $269.
US Bancorp first reported a position in ADC Therapeutics in Q1 2021 and held it in 11 quarters.
US Bancorp's ADC Therapeutics position peaked at $44K in Q1 2021.
37 funds tracked by Wall St. Rank held ADC Therapeutics as of Q4 2023.

Based on US Bancorp's 13F filing for Q4 2023, filed 9 Feb 2024.